BNTX at a glance
BioNTech SE (BNTX, SEC CIK 1776985) filed its latest 20-F annual report on March 10, 2026, a 6-K report on September 18, 2026 and Form 4 insider filings as recently as October 7, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 25 institutional investment managers tracked by SignalX reported holding BioNTech SE (BNTX) shares worth $1.3 billion in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Sahin Ugur on October 7, 2026 of 24,000 shares at $95.86 per share.
- In the last 90 days, BNTX insiders reported 0 open-market purchases ($0) and 24 open-market sales ($78.3M) on Form 4, a net sale of $78.3M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 24 sells
- Net −$78.3M
- 13F holders
- 25 funds
- $1.3B · −1 vs prior quarter
- Latest 6-K
- Sep 18, 2026
- Foreign issuer report
AI 20-F Annual Report Analysis
Latest 20-F, fiscal year ended Dec 31, 2025
Management Discussion & Analysis
- Major shareholders: AT Impf GmbH 101,279,878 shares, 40.3%; Medine GmbH 40,132,788 shares, 16.0%
- All 5% shareholders: 141,412,666 shares, 56.3% of outstanding shares
- Management and Supervisory Boards: 43,042,301 shares, 17.1%
- ATHOS KG de facto control through AT Impf GmbH’s substantial shareholding
- U.S. shareholder ownership unavailable due to limited information from company and depositary
AI summary of the BNTX 20-F filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
SignalX for BNTX
Don't miss the next BNTX filing
- Alerts as it files. A push when BNTX files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut BNTX, by share count.
- Ask anything. An AI agent that reads every BNTX filing and answers with sources.
BNTX alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Sahin Ugur | Sell | Oct 7, 2026 | 24,000 | $95.86 |
| Sahin Ugur | Sell | Oct 6, 2026 | 21,000 | $96.81 |
| Sahin Ugur | Sell | Oct 5, 2026 | 72,000 | $97.23 |
| Sahin Ugur | Sell | Oct 2, 2026 | 17,000 | $96.72 |
| Sahin Ugur | Sell | Oct 1, 2026 | 17,000 | $97.46 |
| Sahin Ugur | Sell | Sep 30, 2026 | 32,000 | $98.12 |
| Sahin Ugur | Sell | Sep 29, 2026 | 34,000 | $98.26 |
| Sahin Ugur | Sell | Sep 28, 2026 | 34,000 | $98.47 |
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate BNTX share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 25 | $1.29B |
| Q1 2026 | 26 | $1.02B |
| Q4 2025 | 25 | $1.10B |
| Q3 2025 | 24 | $1.21B |
| Q2 2025 | 23 | $1.86B |
| Q1 2025 | 23 | $1.52B |
| Q4 2024 | 20 | $1.62B |
| Q3 2024 | 17 | $225.9M |
- FMR LLC (Fidelity)+1.86M (+33%)
- Goldman Sachs Group+493.1K (+509%)
- D.E. Shaw & Co+217.7K (+109%)
- BlackRock+196.8K (+12%)
- Franklin Resources+155.0K (+40%)
- Citadel Advisors LLC−586.8K (-62%)
- Bank of America Corp−416.8K (-46%)
- State Street Corp−17.1K (-9%)
- BNY Mellon−11.8K (-29%)
- U.S. Bancorp−118 (-7%)
- Millennium Management−35.4K
- Northern Trust−16.2K
- Finward Bancorp−2.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 183 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
Latest 2026 SEC Filings: 20-F, 6-K
Related Health Care companies
- FDMT · 4D Molecular Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- ADPT · Adaptive Biotechnologies CorpBiological Products, (No Diagnostic Substances)
- ADMA · ADMA BIOLOGICS, INC.Biological Products, (No Diagnostic Substances)
- ALEC · Alector, Inc.Biological Products, (No Diagnostic Substances)
- ALLO · Allogene Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
- AMGN · AmgenBiological Products, (No Diagnostic Substances)
- AVXL · ANAVEX LIFE SCIENCES CORP.Biological Products, (No Diagnostic Substances)
- APGE · Apogee Therapeutics, Inc.Biological Products, (No Diagnostic Substances)
BNTX SEC filings: frequently asked questions
Are BNTX insiders buying or selling?
In the last 90 days, BioNTech SE (BNTX) officers, directors and 10% owners reported no open-market purchases and 24 open-market sales worth $78.3 million by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold BNTX stock?
As of June 30, 2026, the largest BioNTech SE (BNTX) holders among the 13F filers tracked by SignalX were FMR LLC (Fidelity) ($704.6 million), BlackRock ($172.6 million), Goldman Sachs Group ($54.9 million), Franklin Resources ($50.2 million), Morgan Stanley ($45.8 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest BNTX SEC filings?
BioNTech SE (BNTX) filed its latest 20-F annual report on March 10, 2026, a 6-K report on September 18, 2026 and a Form 4 insider filing on October 7, 2026.
What is BNTX's SEC CIK number?
BioNTech SE (BNTX)'s SEC Central Index Key (CIK) is 1776985. EDGAR lists every BNTX filing under that number.
Ask anything about BNTX
The research agent reads BNTX's filings, financials, insider trades and 13F holders, then answers with sources.